173 related articles for article (PubMed ID: 32344040)
1. Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations.
Vreman RA; de Ruijter AS; Zawada A; Tafuri G; Stoyanova-Beninska V; O'Connor D; Naumann-Winter F; Wolter F; Mantel-Teeuwisse AK; Leufkens HGM; Sidiropoulos I; Larsson K; Goettsch WG
Drug Discov Today; 2020 Jul; 25(7):1223-1231. PubMed ID: 32344040
[TBL] [Abstract][Full Text] [Related]
2. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
Kawalec P; Sagan A; Pilc A
Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
[TBL] [Abstract][Full Text] [Related]
3. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
Nicod E
Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
[TBL] [Abstract][Full Text] [Related]
4. HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries.
Nicod E; Annemans L; Bucsics A; Lee A; Upadhyaya S; Facey K
Health Policy; 2019 Feb; 123(2):140-151. PubMed ID: 28400128
[TBL] [Abstract][Full Text] [Related]
5. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
Joppi R; Bertele' V; Garattini S
Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
[TBL] [Abstract][Full Text] [Related]
6. The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs.
Vreman RA; Bloem LT; van Oirschot S; Hoekman J; van der Elst ME; Leufkens HG; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
Int J Health Policy Manag; 2022 May; 11(5):642-650. PubMed ID: 33131224
[TBL] [Abstract][Full Text] [Related]
7. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
8. Comparing access to orphan medicinal products in Europe.
Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
[TBL] [Abstract][Full Text] [Related]
9. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T; Molnár MJ; Szegedi M; Kaló Z
Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
[TBL] [Abstract][Full Text] [Related]
10. Clinical evidence for orphan medicinal products-a cause for concern?
Picavet E; Cassiman D; Hollak CE; Maertens JA; Simoens S
Orphanet J Rare Dis; 2013 Oct; 8():164. PubMed ID: 24131572
[TBL] [Abstract][Full Text] [Related]
11. The implementation of health technology assessment principles in public decisions concerning orphan drugs.
Brenna E; Polistena B; Spandonaro F
Eur J Clin Pharmacol; 2020 Jun; 76(6):755-764. PubMed ID: 32219539
[TBL] [Abstract][Full Text] [Related]
12. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
[TBL] [Abstract][Full Text] [Related]
13. Establishing rarity in the context of orphan medicinal product designation in the European Union.
Tsigkos S; Hofer MP; Sheean ME; Mariz S; Larsson K; Naumann-Winter F; Fregonese L; Sepodes B
Drug Discov Today; 2018 Mar; 23(3):681-686. PubMed ID: 28647377
[TBL] [Abstract][Full Text] [Related]
14. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
Winstone J; Chadda S; Ralston S; Sajosi P
Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
[TBL] [Abstract][Full Text] [Related]
15. Novel approach to decision making for orphan drugs.
Decker B; Mlcoch T; Pustovalova A; Dolezal T
Int J Technol Assess Health Care; 2023 Feb; 39(1):e10. PubMed ID: 36748356
[TBL] [Abstract][Full Text] [Related]
16. Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): A first step towards a consolidated European perspective on comparative effectiveness & safety?
Chassagnol F; Marcelli G; Wagle J; Giuliani G; Traub D; Schaub V; Ruof J
Health Policy; 2020 Sep; 124(9):943-951. PubMed ID: 32622542
[TBL] [Abstract][Full Text] [Related]
17. Differences in Evidentiary Requirements Between European Medicines Agency and European Health Technology Assessment of Oncology Drugs-Can Alignment Be Enhanced?
Wolters S; Jansman FGA; Postma MJ
Value Health; 2022 Dec; 25(12):1958-1966. PubMed ID: 35752535
[TBL] [Abstract][Full Text] [Related]
18. HEALTH TECHNOLOGY ASSESSMENT IN EVALUATION OF PHARMACEUTICALS IN THE CZECH REPUBLIC.
Vostalová L; Mazelová J; Samek J; Vocelka M
Int J Technol Assess Health Care; 2017 Jan; 33(3):339-344. PubMed ID: 28438231
[TBL] [Abstract][Full Text] [Related]
19. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.
Malinowski KP; Kawalec P; Trąbka W; Sowada C; Petrova G; Manova M; Savova A; Draganić P; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
Orphanet J Rare Dis; 2020 Oct; 15(1):277. PubMed ID: 33032634
[TBL] [Abstract][Full Text] [Related]
20. [European incentives for orphan medicinal products].
Enzmann H; Lütz J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
